Kosky Christopher A, Bonakis Anastasios, Yogendran Arthee, Hettiarachchi Gihan, Dargan Paul I, Williams Adrian J
West Australian Sleep Disorders Research Institute, Sir Charles Gairdner Hospital, Perth, Western Australia.
Sleep Disorders Centre Guys' Hospital, London, UK.
J Clin Sleep Med. 2016 Nov 15;12(11):1499-1505. doi: 10.5664/jcsm.6276.
Drugs and psychoactive substances can cause sleepiness and when undetected, may lead to over diagnosis of central hypersomnias. We performed urine drug testing using gas chromatography-mass spectrometry in adults undergoing multiple sleep latency testing (MSLT) for a suspected central hypersomnia. We examined how the drug test results modified the treating physician's diagnosis.
One hundred eighty-six consecutive patients with a suspected central hypersomnia who underwent clinical assessment, MSLT and urine drug testing by gas chromatography-mass spectrometry were retrospectively studied. Physicians made a diagnosis after clinical assessment and MSLT and were initially blinded to the urine drug test results.
A third of patients assessed for subjective hypersomnia had a positive urine drug test for a substance affecting sleep. Opioids, cannabis, and amphetamines were the commonest drugs detected. Using MSLT, 35 (18.8%) of 186 patients had objective hypersomnia that may have been due to a drug or substance. Drugs or substances may have confounded the MSLT in 11 (20.1%) of 53 patients who fulfilled diagnostic criteria for idiopathic hypersomnia, and 12 (52%) of 23 of those who fulfilled diagnostic criteria for narcolepsy without cataplexy. Of the 75 positive urine drug samples, 61 (81%) were substances or medications not revealed in the physician interview. The treating physician had not suspected drugs or substances as a possible cause of objective hypersomnia in 34 (97%) of the 35 patients.
Drugs and psychoactive substances can confound the results of the MSLT and when undetected could lead to over diagnosis of central hypersomnias.
药物和精神活性物质可导致嗜睡,若未被检测到,可能会导致中枢性睡眠增多症的过度诊断。我们对接受多次睡眠潜伏期试验(MSLT)以排查中枢性睡眠增多症的成年人进行了气相色谱 - 质谱联用的尿液药物检测。我们研究了药物检测结果如何改变主治医生的诊断。
对186例连续接受临床评估、MSLT及气相色谱 - 质谱联用尿液药物检测的疑似中枢性睡眠增多症患者进行回顾性研究。医生在临床评估和MSLT后做出诊断,最初对尿液药物检测结果不知情。
在接受主观嗜睡评估的患者中,三分之一的尿液药物检测呈阳性,检测出的影响睡眠的物质。阿片类药物、大麻和苯丙胺是最常检测到的药物。通过MSLT,186例患者中有35例(18.8%)存在可能由药物或物质导致的客观嗜睡。在符合特发性嗜睡症诊断标准的53例患者中,药物或物质可能混淆了MSLT结果的有11例(20.1%);在符合无猝倒发作型发作性睡病诊断标准的23例患者中,有12例(52%)是这种情况。在75份阳性尿液药物样本中,61份(81%)是医生问诊中未提及的物质或药物。在35例患者中,有34例(97%)的主治医生未怀疑药物或物质是客观嗜睡的可能原因。
药物和精神活性物质会混淆MSLT的结果,若未被检测到,可能会导致中枢性睡眠增多症的过度诊断。